河北医学
河北醫學
하북의학
HEBEI MEDICINE
2014年
6期
955-958
,共4页
紫杉醇%奈达铂%局部晚期鼻咽癌%同期放化疗
紫杉醇%奈達鉑%跼部晚期鼻嚥癌%同期放化療
자삼순%내체박%국부만기비인암%동기방화료
Paelitaxel%Nedaplatin%Nasopharyngeal carcinoma in advanced stage%Concurrent chemoradiotherapy
目的:探讨TP方案(紫杉醇+奈达铂)同期放化疗对局部晚期鼻咽癌的疗效及不良反应。方法:将60例Ⅲ期、ⅣA期的鼻咽癌患者分为TP 组( n=30)和PF(顺铂+氟尿嘧啶)组( n=30)。两组化疗均从放疗的第1天开始,每3-4周化疗1次,两组均化疗2-3个周期。两组的放疗方法相同。分别观察并比较两组的近期疗效和不良反应。结果:TP 组和P F组的1年局部复发率、1年远处转移率、1年肿瘤相关死亡率、1年无疾病进展率分别为3.33%、3.33%、3.33%、96.33%和6.67%、3.33%、3.33%、90.00%,两组比较无显著性差异( P>0.05)。 TP 组和PF组在血液毒性及肝脏毒性方面无显著性差异(P>0.05);口腔粘膜反应及呕吐方面PF组较TP组显著增多(P<0.05)。结论:TP 方案在疗效上与经典的P F方案相当,在减少不良反应方面TP方案有更好的优势。
目的:探討TP方案(紫杉醇+奈達鉑)同期放化療對跼部晚期鼻嚥癌的療效及不良反應。方法:將60例Ⅲ期、ⅣA期的鼻嚥癌患者分為TP 組( n=30)和PF(順鉑+氟尿嘧啶)組( n=30)。兩組化療均從放療的第1天開始,每3-4週化療1次,兩組均化療2-3箇週期。兩組的放療方法相同。分彆觀察併比較兩組的近期療效和不良反應。結果:TP 組和P F組的1年跼部複髮率、1年遠處轉移率、1年腫瘤相關死亡率、1年無疾病進展率分彆為3.33%、3.33%、3.33%、96.33%和6.67%、3.33%、3.33%、90.00%,兩組比較無顯著性差異( P>0.05)。 TP 組和PF組在血液毒性及肝髒毒性方麵無顯著性差異(P>0.05);口腔粘膜反應及嘔吐方麵PF組較TP組顯著增多(P<0.05)。結論:TP 方案在療效上與經典的P F方案相噹,在減少不良反應方麵TP方案有更好的優勢。
목적:탐토TP방안(자삼순+내체박)동기방화료대국부만기비인암적료효급불량반응。방법:장60례Ⅲ기、ⅣA기적비인암환자분위TP 조( n=30)화PF(순박+불뇨밀정)조( n=30)。량조화료균종방료적제1천개시,매3-4주화료1차,량조균화료2-3개주기。량조적방료방법상동。분별관찰병비교량조적근기료효화불량반응。결과:TP 조화P F조적1년국부복발솔、1년원처전이솔、1년종류상관사망솔、1년무질병진전솔분별위3.33%、3.33%、3.33%、96.33%화6.67%、3.33%、3.33%、90.00%,량조비교무현저성차이( P>0.05)。 TP 조화PF조재혈액독성급간장독성방면무현저성차이(P>0.05);구강점막반응급구토방면PF조교TP조현저증다(P<0.05)。결론:TP 방안재료효상여경전적P F방안상당,재감소불량반응방면TP방안유경호적우세。
Objective:To evaluate the efficacy and adverse reactions of paclitaxel and nedaplatin chem-otherapy in combination with concurrent radiotherapy for nasopharyngeal carcinoma of stage Ⅲ and IVa. Method:A total of 60 patients with advanced nasopharyngeal carcinoma were divided into group TP ( n=30) and group PF(n=30).The two groups were treated with regimens every 3 weeks or 4 weeks as a cycle.The two groups of patients received two or three cycles .The chemotherapy of the two groups begin with the first day of radiotherapy .Both groups were given the same radiotherapy .and then evaluated the efficacy and adverse reactions of the two groups .Result: The 1-year recurrence from local regional failure survival rate , l-year distant metastasis rate , 1-year of tumor related mortality and 1-year free distant metastasis survival rate of group TP and group PF were respectively 3.33%, 3.33%, 3.33%, 96.33%and 6.67%, 3.33%, 3.33%,90. 00%.There was no difference between them in statistics (P>0.05).There was no differenc between the two groups in hematolgic toxicity and hepatotoxicity in statistics ( P>0.05) .Group PF was worse than group TP in the oral mucosa reaction and vomiting ( P<0.05) .Conclusion:There was no difference between TP and PF in the efficacy in statistics .TP was better than PF in the adverse reactions .